A Phase 1 interventional study of HRS-7085 tablets and Placebo tablet in Inflammatory Bowel Disease, sponsored by Atridia Pty Ltd.. Completed at 1 site in Australia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-21.
Sponsored by Atridia Pty Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies in Inflammatory Bowel Diseases with a site in Australia — 11 open to participants now, 13 under way, 3 of them phase 3. Inflammatory Bowel Diseases · Australia.
Among the 54 studies in Inflammatory Bowel Diseases with a site in Australia, this one is the 48th largest by enrollment of the 49 interventional ones that give a count, is one of 4 that started in 2022, is one of 7 in phase 1, and was the 41st registered.
1,550 studies on the registry are indexed under Inflammatory Bowel Diseases; 423 are open to participants now.
Browse Inflammatory Bowel Diseases studies →11 of the 54 studies in Inflammatory Bowel Diseases with a site in Australia are open now. Recruiting first, the newest first:
Xencor, Inc. · Sites in Australia
Ages 18–55 · Healthy volunteers
Austin Health · Sites in Australia
Ages 18+ · Women only
Parvus Therapeutics, Inc. · Sites in Australia
Ages 18–65 · Healthy volunteers
Odyssey Therapeutics · Sites in Australia, Austria, Canada and 7 more countries
Ages 18–75
Spyre Therapeutics, Inc. · Sites in Australia, United States, Argentina and 32 more countries
Ages 18–75
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 276 Inflammatory Bowel Diseases studies recruiting now, 133 (48%) set no upper age limit and 116 (42%) stop at 75 or younger; 76 take children under 18; 61 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 20 · Phase 3 18 · Phase 4 2
First in 2005; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 16 is below the median of 68 across 870 interventional studies indexed under Inflammatory Bowel Diseases.
Median enrollment 139 across the 49 interventional studies, 119 across the 5 observational. Of the 36 that completed or were terminated, 22 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
40 of 54 have an industry lead sponsor. The 10 most frequent:
This study is registered under Atridia Pty Ltd., one of the names counted as Jiangsu HengRui Medicine Co., Ltd.. Under that name alone:
Atridia Pty Ltd. is the lead sponsor of 36 studies on the registry; 2 are open to participants now.
Jiangsu HengRui Medicine Co., Ltd. has 2 studies filed under Inflammatory Bowel Diseases — fewer than ten, so there is no comparison to draw.
4 of the studies in Inflammatory Bowel Diseases with a site in Australia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05923073Phase 3Janssen Research & Development, LLCA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease | 2027-10-27 |
| NCT07012395Spyre Therapeutics, Inc.A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis | 2027-06 |
| NCT07713485Xencor, Inc.Study of XmAb412 in Healthy Participants | 2027-08 |
| NCT07423000Parvus Therapeutics, Inc.A Phase 1 Study of PVT401 in Healthy Subjects | 2027-11 |
Add all 4 to your calendar (.ics) → With an account.
Among the 54 studies in Inflammatory Bowel Diseases with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study is being conducted to evaluate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of HRS-7085.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Part 1- HRS-7085 tablets
Drug: HRS-7085 tablets · Drug: Placebo tablet
Part 1- HRS-7085 tablets
Drug: HRS-7085 tablets · Drug: Placebo tablet
Single oral administration
Single oral administration
Incidence and severity of adverse events
Time frame: Start of Treatment to end of study approximately 1 week
Pharmacokinetics-AUC0-last
Area under the concentration-time curve from time 0 to last time point after HRS-7085 administration
Time frame: Start of Treatment to end of study (approximately 1 week)
Pharmacokinetics-AUC0-inf
Area under the concentration-time curve from time 0 to infinity after HRS-7085 administration
Time frame: Start of Treatment to end of study (approximately 1 week)
Pharmacokinetics-Tmax
Time to Cmax of HRS-7085
Time frame: Start of Treatment to end of study (approximately 1 week)
Pharmacokinetics-Cmax
Maximum observed concentration of HRS-7085
Time frame: Time Frame: Start of Treatment to end of study (approximately 1 week)
Pharmacokinetics-CL/F
Apparent clearance of HRS-7085
Time frame: Time Frame: Start of Treatment to end of study (approximately 1 week)
Pharmacokinetics-Vz/F
Apparent volume of distribution during terminal phase of HRS-7085
Time frame: Time Frame: Start of Treatment to end of study (approximately 1 week)
Pharmacokinetics-t1/2
Terminal elimination half-life of HRS-7085
Time frame: Time Frame: Start of Treatment to end of study (approximately 1 week)
Ran from Dec 2022 to primary completion in Mar 2023, 3 months.
Of 35 industry-sponsored phase 1 interventional studies under Inflammatory Bowel Diseases, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 13. This study's 3 months is below that.
Counting every sponsor, half of 51 studies reached it within 12 months; a quarter within 4 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: HRS-7085